SuperworthMedline Inc. MDLN
Medical - Instruments & Supplies, Healthcare
$35.45
−0.28%
- Market cap
- $46.6B
- PE
- 41.2×
- Forward PE
- Price to sales
- 1.6×
- EV/EBIT
- 35.5×
- Revenue, 12 months
- $29.9B
- Net margin
- —
- Free cash flow yield
- 2.9%
Medline trades at 41.2× trailing earnings. Revenue was $29.9B over the last twelve months.
Charts
Financials
| Income statement | Q2 FY24 | Q3 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|
| $6.2B | $6.4B | $6.6B | $6.9B | $7.1B | $7.8B | $7.4B+11% | $7.7B+12% | |
| Cost of revenue | $4.7B | $4.8B | $4.8B | $5B | $5.4B | $5.9B | $5.5B+14% | $5.5B+10% |
| Gross profit | $1.5B | $1.6B | $1.8B | $1.9B | — | — | $1.8B+1% | $2.2B+16% |
| SG&A | $976M | $988M | $1.1B | $1.1B | $1.1B | $1.3B | $1.2B+15% | $1.3B+21% |
| $516M | $574M | $571M | $642M | $574M | $425M | $422M−26% | $395M−39% | |
| Interest expense | $267M | $174M | $214M | $233M | $228M | $166M | $165M−23% | $168M−28% |
| Pre-tax income | $300M | $338M | $338M | $359M | $345M | $206M | $291M−14% | $235M−35% |
| $8M | $14M | $16M | $26M | $23M | $26M | $52M+225% | $96M+269% | |
| Net income | $292M | $324M | $322M | $333M | — | — | $239M−26% | $139M−58% |
| $0.37 | $0.41 | $0.40 | $0.42 | $0.41 | $0.22 | $0.16−60% | $0.07−83% | |
| 787.1M | 787.1M | 799.8M | 787.1M | 787.1M | 812M | 824.8M+3% | 860.9M+9% |
From each company's 10-Q and 10-K filings. Fiscal years are four fiscal quarters added up; balance sheet lines are as of the period's end. Growth is on the same period a year earlier.
Estimates
Next earnings report: .
Analyst consensus for the next eight quarters, with the range from the lowest to the highest estimate, is part of Superworth Pro.
Peers
Companies in Medical - Instruments & Supplies within ten times Medline's size, closest in size first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| MDLNMedline Inc. | $46.6B | 41.2× | 32.3× | 1.6× | +15% | — | |
| BDXBecton, Dickinson and Company | $49.1B | 54.3× | 47.3× | 2.4× | −3% | 4.5% | |
| RMDResMed Inc. | $32.6B | 21.7× | 37.3× | 5.8× | +10% | 26.9% | |
| WSTWest Pharmaceutical Services, Inc. | $25.8B | 46.9× | 45.8× | 7.8× | +12% | 17.0% | |
| ISRGIntuitive Surgical, Inc. | $146.4B | 47.5× | 69.0× | 13.3× | +21% | 28.4% | |
| Peer median | $40.8B | 47.2× | 46.6× | 6.8× | +11% | 22.0% |
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .